Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study).

ABSTRACT:

Introduction

The renoprotective effects of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with renal dysfunction are unexamined. We evaluated the efficacy of luseogliflozin in slowing renal function decline among patients with type 2 diabetes mellitus and moderate to severe renal dysfunction.

Materials and methods

In a multicenter, randomized, open-label, controlled clinical trial, patients with type 2 diabetes mellitus and an estimated glomerular filtration rate based on serum creatinine (eGFRcreat) of 15-45 mL/min/1.73 m² were randomized into luseogliflozin or control groups. The primary endpoint was the change in eGFRcreat from baseline to 104 weeks. Secondary endpoints included eGFRcreat and eGFRcreat slope changes from 4 to 104 weeks

SUBMITTER: Kitada M 

PROVIDER: S-EPMC12679181 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature